NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Sara Pellegrino (investors) Executive Vice President, COO (646) 536-7002 and CFO spellegrino@theruthgroup.comRoyalty Financing Agreement • May 6th, 2010 • NeurogesX Inc • Pharmaceutical preparations
San Mateo, Calif., (April 30, 2010) – NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that it has entered into a $40 million royalty financing agreement with Cowen Healthcare Royalty Partners, L.P. (“Cowen Royalty”). The agreement creates a debt obligation that will be repaid through and secured by royalties and future milestone payments payable to NeurogesX under its Distribution, Marketing and License Agreement (the Astellas Agreement) with Astellas Pharma Europe Ltd. (Astellas) for NeurogesX’ Qutenza® (capsaicin) 8% patch, a dermal delivery system containing prescription strength capsaicin.
